We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant tumor shrinkage and one patient with...
Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio Submissions to Health Canada planned for 2025 MONTREAL, Dec. 04, 2024 (GLOBE...
MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
New financing replaces existing credit facility to optimize Company’s capital structureFavorable interest rates and amortization schedules to free up approximately $19 million in cash in 2025 to...
Resubmission addresses questions raised in January 2024 Complete Response Letter F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in...
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
Q3 revenue of $22.6 million represents +8% growth year-over-yearPositive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million Fiscal 2024 guidance revised to...
MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.18 | 8.37209302326 | 2.15 | 2.4 | 1.97 | 55813 | 2.13631958 | CS |
4 | 0.64 | 37.8698224852 | 1.69 | 2.4 | 1.6 | 49736 | 1.98179101 | CS |
12 | 0.66 | 39.5209580838 | 1.67 | 2.4 | 1.6 | 45899 | 1.8126285 | CS |
26 | 0.59 | 33.908045977 | 1.74 | 2.4 | 1.59 | 33645 | 1.82967304 | CS |
52 | 0.2 | 9.3896713615 | 2.13 | 3.43 | 1.59 | 31648 | 1.99511429 | CS |
156 | -14.15 | -85.8616504854 | 16.48 | 16.68 | 1.22 | 35873 | 4.56739974 | CS |
260 | -13.67 | -85.4375 | 16 | 22.4 | 1.22 | 66770 | 10.79172315 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions